



Notification

6499 / 6502 / 6508 / 6510 / 6512

Category

HCPCS - Drugs & Biologicals

Topic

Louisiana Medicaid – Injection, eculizumab, 10 mg

<u>HUM</u>	<u>6499</u>	<u>Injection, eculizumab, 10mg</u>	<u>We limit reimbursement of charges for eculizumab, 10 mg, to no more than 150 units every 6 weeks for patients younger than 2 if the diagnosis on claim is atypical hemolytic uremic syndrome</u>
<u>HUM</u>	<u>6502</u>	<u>Injection, eculizumab, 10mg</u>	<u>We limit reimbursement of charges for eculizumab, 10 mg, to no more than 240 units every 6 weeks for patients ages 2 – 4 if the diagnosis on claim is atypical hemolytic uremic syndrome.</u>
<u>HUM</u>	<u>6508</u>	<u>Injection, eculizumab, 10mg</u>	<u>We limit reimbursement of charges for eculizumab, 10 mg, to no more than 330 units every 6 weeks for patients aged 5 years if the diagnosis on claim is atypical hemolytic uremic syndrome.</u>
<u>HUM</u>	<u>6510</u>	<u>Injection, eculizumab, 10mg</u>	<u>We limit reimbursement of charges for eculizumab, 10 mg, to no more than 480 units every 6 weeks for patients 6 or older if the diagnosis on claim is atypical hemolytic uremic syndrome.</u>
<u>HUM</u>	<u>6512</u>	<u>Injection, eculizumab, 10mg</u>	<u>We limit reimbursement of charges for eculizumab, 10 mg, to no more than 1,680 units every 26 weeks if either of the following diagnoses are billed:</u> <ul style="list-style-type: none"><u>• Myasthenia gravis</u><u>• Neuromyelitis optica spectrum</u>

Language

English

Impacted Products

Medicaid – Louisiana

Why is Humana making this change?

These limitations were established by the FDA-approved package insert and prescribing information or the pharmaceutical compendia.